Literature DB >> 9093584

Malignant hyperthermia susceptibility: anaesthetic implications and risk stratification.

R Ben Abraham1, A Cahana, R M Krivosic-Horber, A Perel.   

Abstract

Malignant hyperthermia (MH) is a rare autosomal dominant trait that predisposes individuals to great danger when exposed to certain anaesthetic triggering agents, such as potent volatile anaesthetics and succinylcholine. Sudden hypermetabolic reaction occurs in skeletal muscle, leading to hyperthermia and massive rhabdomyolysis. Precautions must be taken before the anaesthesia of MH-susceptible patients. No triggering agents should be administered, central body temperature and ETCO2 should be carefully monitored, and dantrolene must be immediately available. In addition, the anaesthesia machine should be carefully washed to remove traces of halogenated agents, and the use of fresh disposable anaesthetic circuits is recommended. Early diagnosis of the syndrome by alert, informed anaesthesiologists, and the immediate administration of dantrolene and other supportive measures, has reduced mortality. Patients with MH susceptibility should be instructed to alert the anaesthesiologist about their condition whenever anaesthesia is needed. Although people diagnosed with MH susceptibility should not change their lifestyle in general, military service is limited.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9093584     DOI: 10.1093/qjmed/90.1.13

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  5 in total

Review 1.  Acp. Best practice no 155. Pathological investigation of deaths following surgery, anaesthesia, and medical procedures.

Authors:  R D Start; S S Cross
Journal:  J Clin Pathol       Date:  1999-09       Impact factor: 3.411

2.  Oxidative capacity and fatigability in run-trained malignant hyperthermia-susceptible mice.

Authors:  Clement Rouviere; Benjamin T Corona; Christopher P Ingalls
Journal:  Muscle Nerve       Date:  2012-04       Impact factor: 3.217

Review 3.  Adverse reactions to neuromuscular blocking agents.

Authors:  Paul-Michel Mertes; Marie Claire Laxenaire
Journal:  Curr Allergy Asthma Rep       Date:  2004-01       Impact factor: 4.919

Review 4.  Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Authors:  Ana L Huerta-Alardín; Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2004-10-20       Impact factor: 9.097

5.  Recommended practices for cleaning, handling and processing anesthesia equipment.

Authors: 
Journal:  AORN J       Date:  2005-04       Impact factor: 0.676

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.